Sanofi: exclusive licensing agreement with Vir Biotechnology

(CercleFinance.com) - US biotech Vir Biotechnology announced Thursday evening the signature of an exclusive worldwide licensing agreement with French pharmaceutical group Sanofi.


The agreement covers the exclusive use of three T cell recruiters (TCEs) discovered by Vir for the development of the immuno-oncology portfolio and biological agents acquired by Sanofi from Amunix Pharmaceuticals.

These are SAR446309 (in phase 1 in breast and colorectal cancers), SAR446329 (in phase 1 in prostate cancer) and SAR446368 (in phase 1 in several cancers including renal cell carcinoma), according to the press release.

The aim, according to the two partners, will be to exploit the high protease activity of the tumor microenvironment to specifically activate drugs in tumor tissue.

With the use of T-cell recruiters (TCEs), Vir says it wants to solve the ever-important problem of cancer treatment toxicity.

Copyright (c) 2024 CercleFinance.com. All rights reserved.